Valproate, women, and exceptional circumstances

Heather Angus-Leppan; Rohit Shankar; Hannah Cock

doi:10.1136/bmj.k3625

Valproate, women, and exceptional circumstances

Heather Angus-Leppan, Rohit Shankar, Hannah Cock

Peninsula Medical School

Research output: Contribution to journal › Letter › peer-review

Abstract

The Medicines and Healthcare Products Regulatory Agency (MHRA) now requires women of childbearing potential who take valproate to provide annual signed confirmation of adherence to the pregnancy prevention programme. The detail that for “for some women with epilepsy, it may not be possible to stop valproate, and they may have to continue treatment (with appropriate specialist care) in pregnancy”1 is crucial and from our experience seems to be sometimes overlooked.

Original language	English
Article number	k3625
Journal	BMJ (Online)
Volume	362
DOIs	https://doi.org/10.1136/bmj.k3625
Publication status	Published - 28 Aug 2018

ASJC Scopus subject areas

General Medicine

Access to Document

10.1136/bmj.k3625

Cite this

@article{9ccdaf9afd474998bc6f16563a20efba,

title = "Valproate, women, and exceptional circumstances",

abstract = "The Medicines and Healthcare Products Regulatory Agency (MHRA) now requires women of childbearing potential who take valproate to provide annual signed confirmation of adherence to the pregnancy prevention programme. The detail that for “for some women with epilepsy, it may not be possible to stop valproate, and they may have to continue treatment (with appropriate specialist care) in pregnancy”1 is crucial and from our experience seems to be sometimes overlooked.",

author = "Heather Angus-Leppan and Rohit Shankar and Hannah Cock",

year = "2018",

month = aug,

day = "28",

doi = "10.1136/bmj.k3625",

language = "English",

volume = "362",

journal = "BMJ (Online)",

issn = "0959-8146",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Valproate, women, and exceptional circumstances

AU - Angus-Leppan, Heather

AU - Shankar, Rohit

AU - Cock, Hannah

PY - 2018/8/28

Y1 - 2018/8/28

N2 - The Medicines and Healthcare Products Regulatory Agency (MHRA) now requires women of childbearing potential who take valproate to provide annual signed confirmation of adherence to the pregnancy prevention programme. The detail that for “for some women with epilepsy, it may not be possible to stop valproate, and they may have to continue treatment (with appropriate specialist care) in pregnancy”1 is crucial and from our experience seems to be sometimes overlooked.

AB - The Medicines and Healthcare Products Regulatory Agency (MHRA) now requires women of childbearing potential who take valproate to provide annual signed confirmation of adherence to the pregnancy prevention programme. The detail that for “for some women with epilepsy, it may not be possible to stop valproate, and they may have to continue treatment (with appropriate specialist care) in pregnancy”1 is crucial and from our experience seems to be sometimes overlooked.

UR - http://www.scopus.com/inward/record.url?scp=85052621190&partnerID=8YFLogxK

U2 - 10.1136/bmj.k3625

DO - 10.1136/bmj.k3625

M3 - Letter

C2 - 30154117

AN - SCOPUS:85052621190

SN - 0959-8146

VL - 362

JO - BMJ (Online)

JF - BMJ (Online)

M1 - k3625

ER -

Valproate, women, and exceptional circumstances

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this